| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Monte Rosa Therapeutics, Inc.
13G/A
Amendment 1
GLUE · 61225M102
|
9.2% |
5/15/2025
Event 3/31/2025
|
|||
| Biotechnology Value Fund L P | 4.7% | ||||
| BVF I GP LLC | 4.7% | ||||
| Biotechnology Value Fund II LP | 3.8% | ||||
| BVF II GP LLC | 3.8% | ||||
| Biotechnology Value Trading Fund OS LP | 0.5% | ||||
| BVF Partners OS Ltd. | 0.5% | ||||
| BVF GP Holdings LLC | 8.5% | ||||
| BVF Partners L P/IL | 9.2% | ||||
| BVF Inc/IL | 9.2% | ||||
| Lampert Mark N | 9.2% | ||||
|
GH Research PLC
13G/A
Amendment 2
GHRS · G3855L106
|
14.2% |
5/15/2025
Event 3/31/2025
|
|||
| Biotechnology Value Fund L P | 7.4% | ||||
| BVF I GP LLC | 7.4% | ||||
| Biotechnology Value Fund II LP | 5.8% | ||||
| BVF II GP LLC | 5.8% | ||||
| Biotechnology Value Trading Fund OS LP | 1.0% | ||||
| BVF Partners OS Ltd. | 1.0% | ||||
| BVF GP Holdings LLC | 13.2% | ||||
| BVF Partners L P/IL | 14.2% | ||||
| BVF Inc/IL | 14.2% | ||||
| Lampert Mark N | 14.2% | ||||
|
4D Molecular Therapeutics, Inc.
13G/A
Amendment 5
FDMT · 35104E100
|
10.0% |
5/15/2025
Event 3/31/2025
|
|||
| Biotechnology Value Fund L P | 5.0% | ||||
| BVF I GP LLC | 5.0% | ||||
| Biotechnology Value Fund II LP | 4.1% | ||||
| BVF II GP LLC | 4.1% | ||||
| Biotechnology Value Trading Fund OS LP | 0.6% | ||||
| BVF Partners OS Ltd. | 0.6% | ||||
| BVF GP Holdings LLC | 9.1% | ||||
| BVF Partners L P/IL | 10.0% | ||||
| BVF Inc/IL | 10.0% | ||||
| Lampert Mark N | 10.0% | ||||
|
Elevation Oncology, Inc.
13G/A
Amendment 4
ELEV · 28623U101
|
7.0% |
5/15/2025
Event 3/31/2025
|
|||
| Biotechnology Value Fund L P | 3.9% | ||||
| BVF I GP LLC | 3.9% | ||||
| Biotechnology Value Fund II LP | 3.0% | ||||
| BVF II GP LLC | 3.0% | ||||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||||
| BVF Partners OS Ltd. | 0.4% | ||||
| BVF GP Holdings LLC | 6.6% | ||||
| BVF Partners L P/IL | 7.0% | ||||
| BVF Inc/IL | 7.0% | ||||
| Lampert Mark N | 7.0% | ||||
|
Cidara Therapeutics, Inc.
13G/A
Amendment 8
CDTX · 171757206
|
10.0% |
5/15/2025
Event 3/31/2025
|
|||
| Biotechnology Value Fund L P | 5.8% | ||||
| BVF I GP LLC | 5.8% | ||||
| Biotechnology Value Fund II LP | 3.8% | ||||
| BVF II GP LLC | 3.8% | ||||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||||
| BVF Partners OS Ltd. | 0.4% | ||||
| BVF GP Holdings LLC | 9.4% | ||||
| BVF Partners L P/IL | 10.0% | ||||
| BVF Inc/IL | 10.0% | ||||
| Lampert Mark N | 10.0% | ||||
|
Inventiva S.A.
13D/A
Amendment 5
IVA · 46124U107
|
6.1% |
5/9/2025
Event 5/7/2025
|
|||
| Biotechnology Value Fund L P | 3.3% | ||||
| BVF I GP LLC | 3.3% | ||||
| Biotechnology Value Fund II LP | 2.4% | ||||
| BVF II GP LLC | 2.4% | ||||
| Biotechnology Value Trading Fund OS LP | 0.3% | ||||
| BVF Partners OS Ltd. | 0.3% | ||||
| BVF GP Holdings LLC | 5.7% | ||||
| BVF Partners L P/IL | 6.1% | ||||
| BVF Inc/IL | 6.1% | ||||
| Lampert Mark N | 6.1% | ||||
|
Third Harmonic Bio, Inc.
13G/A
Amendment 3
THRD · 88427A107
|
0% |
4/16/2025
Event 4/14/2025
|
|||
| Biotechnology Value Fund L P | 0% | ||||
| BVF I GP LLC | 0% | ||||
| Biotechnology Value Fund II LP | 0% | ||||
| BVF II GP LLC | 0% | ||||
| Biotechnology Value Trading Fund OS LP | 0% | ||||
| BVF Partners OS Ltd. | 0% | ||||
| BVF GP Holdings LLC | 0% | ||||
| BVF Partners L P/IL | 0% | ||||
| BVF Inc/IL | 0% | ||||
| Lampert Mark N | 0% | ||||
|
ESSA Pharma Inc.
13D
EPIX · 29668H708
|
19.7% |
4/9/2025
Event 4/9/2025
|
|||
| Biotechnology Value Fund LP | 10.6% | ||||
| BVF I GP LLC | 10.6% | ||||
| Biotechnology Value Fund II LP | 7.9% | ||||
| BVF II GP LLC | 7.9% | ||||
| Biotechnology Value Trading Fund OS LP | 0.8% | ||||
| BVF Partners OS Ltd. | 0.8% | ||||
| BVF GP Holdings LLC | 18.5% | ||||
| BVF Partners L P/IL | 19.7% | ||||
| BVF Inc/IL | 19.7% | ||||
| Lampert Mark N | 19.7% | ||||
|
Vistagen Therapeutics, Inc.
13G/A
Amendment 1
VTGN · 92840H400
|
10.0% |
2/14/2025
Event 12/31/2024
|
|||
| Biotechnology Value Fund L P | 5.4% | ||||
| BVF I GP LLC | 5.4% | ||||
| Biotechnology Value Fund II LP | 4.4% | ||||
| BVF II GP LLC | 4.4% | ||||
| Biotechnology Value Trading Fund OS LP | 0.6% | ||||
| BVF Partners OS Ltd. | 0.6% | ||||
| BVF GP Holdings LLC | 9.4% | ||||
| BVF Partners L P/IL | 10.0% | ||||
| BVF Inc/IL | 10.0% | ||||
| Lampert Mark N | 10.0% | ||||
|
Verastem, Inc.
13G/A
Amendment 8
VSTM · 92337C203
|
10.0% |
2/14/2025
Event 12/31/2024
|
|||
| Biotechnology Value Fund L P | 6.0% | ||||
| BVF I GP LLC | 6.0% | ||||
| Biotechnology Value Fund II LP | 3.8% | ||||
| BVF II GP LLC | 3.8% | ||||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||||
| BVF Partners OS Ltd. | 0.4% | ||||
| BVF GP Holdings LLC | 9.5% | ||||
| BVF Partners L P/IL | 10.0% | ||||
| BVF Inc/IL | 10.0% | ||||
| Lampert Mark N | 10.0% | ||||
|
Tyra Biosciences, Inc.
13G/A
Amendment 3
TYRA · 90240B106
|
7.8% |
2/14/2025
Event 12/31/2024
|
|||
| Biotechnology Value Fund L P | 4.0% | ||||
| BVF I GP LLC | 4.0% | ||||
| Biotechnology Value Fund II LP | 3.2% | ||||
| BVF II GP LLC | 3.2% | ||||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||||
| BVF Partners OS Ltd. | 0.4% | ||||
| BVF GP Holdings LLC | 7.3% | ||||
| BVF Partners L P/IL | 7.8% | ||||
| BVF Inc/IL | 7.8% | ||||
| Lampert Mark N | 7.8% | ||||
|
Ikena Oncology, Inc.
13G/A
Amendment 4
IKNA · 45175G108
|
8.3% |
2/14/2025
Event 12/31/2024
|
|||
| Biotechnology Value Fund L P | 4.3% | ||||
| BVF I GP LLC | 4.3% | ||||
| Biotechnology Value Fund II LP | 3.5% | ||||
| BVF II GP LLC | 3.5% | ||||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||||
| BVF Partners OS Ltd. | 0.4% | ||||
| BVF GP Holdings LLC | 7.7% | ||||
| BVF Partners L P/IL | 8.3% | ||||
| BVF Inc/IL | 8.3% | ||||
| Lampert Mark N | 8.3% | ||||
|
4D Molecular Therapeutics, Inc.
13G/A
Amendment 4
FDMT · 35104E100
|
10.0% |
2/14/2025
Event 12/31/2024
|
|||
| Biotechnology Value Fund L P | 7.1% | ||||
| BVF I GP LLC | 7.1% | ||||
| Biotechnology Value Fund II LP | 2.4% | ||||
| BVF II GP LLC | 2.4% | ||||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||||
| BVF Partners OS Ltd. | 0.4% | ||||
| BVF GP Holdings LLC | 9.4% | ||||
| BVF Partners L P/IL | 10.0% | ||||
| BVF Inc/IL | 10.0% | ||||
| Lampert Mark N | 10.0% | ||||
|
Forte Biosciences, Inc.
13G/A
Amendment 1
FBRX · 34962G208
|
10.0% |
2/14/2025
Event 12/31/2024
|
|||
| Biotechnology Value Fund L P | 5.3% | ||||
| BVF I GP LLC | 5.3% | ||||
| Biotechnology Value Fund II LP | 4.1% | ||||
| BVF II GP LLC | 4.1% | ||||
| Biotechnology Value Trading Fund OS LP | 0.5% | ||||
| BVF Partners OS Ltd. | 0.5% | ||||
| BVF GP Holdings LLC | 9.3% | ||||
| BVF Partners L P/IL | 10.0% | ||||
| BVF Inc/IL | 10.0% | ||||
| Lampert Mark N | 10.0% | ||||
|
89bio, Inc.
13G/A
Amendment 4
ETNB · 282559103
|
3.6% |
2/14/2025
Event 12/31/2024
|
|||
| Biotechnology Value Fund L P | 1.9% | ||||
| BVF I GP LLC | 1.9% | ||||
| Biotechnology Value Fund II LP | 1.5% | ||||
| BVF II GP LLC | 1.5% | ||||
| Biotechnology Value Trading Fund OS LP | 0.2% | ||||
| BVF Partners OS Ltd. | 0.2% | ||||
| BVF GP Holdings LLC | 3.4% | ||||
| BVF Partners L P/IL | 3.6% | ||||
| BVF Inc/IL | 3.6% | ||||
| Lampert Mark N | 3.6% | ||||
|
Cidara Therapeutics, Inc.
13G/A
Amendment 7
CDTX · 171757206
|
10.0% |
2/14/2025
Event 12/31/2024
|
|||
| Biotechnology Value Fund L P | 4.5% | ||||
| BVF I GP LLC | 4.5% | ||||
| Biotechnology Value Fund II LP | 4.5% | ||||
| BVF II GP LLC | 4.5% | ||||
| Biotechnology Value Trading Fund OS LP | 0.6% | ||||
| BVF Partners OS Ltd. | 0.6% | ||||
| BVF GP Holdings LLC | 9.0% | ||||
| BVF Partners L P/IL | 10.0% | ||||
| BVF Inc/IL | 10.0% | ||||
| Lampert Mark N | 10.0% | ||||
|
Avalo Therapeutics, Inc.
13G/A
Amendment 1
AVTX · 05338F306
|
10.0% |
2/14/2025
Event 12/31/2024
|
|||
| Biotechnology Value Fund L P | 5.3% | ||||
| BVF I GP LLC | 5.3% | ||||
| Biotechnology Value Fund II LP | 4.2% | ||||
| BVF II GP LLC | 4.2% | ||||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||||
| BVF Partners OS Ltd. | 0.4% | ||||
| BVF GP Holdings LLC | 9.5% | ||||
| BVF Partners L P/IL | 10.0% | ||||
| BVF Inc/IL | 10.0% | ||||
| Lampert Mark N | 10.0% | ||||
|
Kura Oncology, Inc.
13G
KURA · 50127T109
|
7.5% |
2/4/2025
Event 1/27/2025
|
|||
| Biotechnology Value Fund L P | 3.9% | ||||
| BVF I GP LLC | 3.9% | ||||
| Biotechnology Value Fund II LP | 3.1% | ||||
| BVF II GP LLC | 3.1% | ||||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||||
| BVF Partners OS Ltd. | 0.4% | ||||
| BVF GP Holdings LLC | 7.0% | ||||
| BVF Partners L P/IL | 7.5% | ||||
| BVF Inc/IL | 7.5% | ||||
| Lampert Mark N | 7.5% | ||||
|
Kura Oncology, Inc.
13G/A
Amendment 4
KURA · 50127T109
|
4.3% |
2/4/2025
Event 12/31/2024
|
|||
| Biotechnology Value Fund L P | 2.2% | ||||
| BVF I GP LLC | 2.2% | ||||
| Biotechnology Value Fund II LP | 1.8% | ||||
| BVF II GP LLC | 1.8% | ||||
| Biotechnology Value Trading Fund OS LP | 0.2% | ||||
| BVF Partners OS Ltd. | 0.2% | ||||
| BVF GP Holdings LLC | 4.0% | ||||
| BVF Partners L P/IL | 4.3% | ||||
| BVF Inc/IL | 4.3% | ||||
| Lampert Mark N | 4.3% | ||||
|
Monte Rosa Therapeutics, Inc.
13G
GLUE · 61225M102
|
7.2% |
1/31/2025
Event 1/24/2025
|
|||
| Biotechnology Value Fund L P | 3.7% | ||||
| BVF I GP LLC | 3.7% | ||||
| Biotechnology Value Fund II LP | 3.0% | ||||
| BVF II GP LLC | 3.0% | ||||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||||
| BVF Partners OS Ltd. | 0.4% | ||||
| BVF GP Holdings LLC | 6.6% | ||||
| BVF Partners L P/IL | 7.2% | ||||
| BVF Inc/IL | 7.2% | ||||
| Lampert Mark N | 7.2% | ||||
|
enGene Holdings Inc.
13G/A
Amendment 3
ENGN · 29286M105
|
1.8% |
1/29/2025
Event 1/27/2025
|
|||
| Biotechnology Value Fund L P | 1.0% | ||||
| BVF I GP LLC | 1.0% | ||||
| Biotechnology Value Fund II LP | 0.7% | ||||
| BVF II GP LLC | 0.7% | ||||
| Biotechnology Value Trading Fund OS LP | 0.1% | ||||
| BVF Partners OS Ltd. | 0.1% | ||||
| BVF GP Holdings LLC | 1.7% | ||||
| BVF Partners L P/IL | 1.8% | ||||
| BVF Inc/IL | 1.8% | ||||
| Lampert Mark N | 1.8% | ||||
|
enGene Holdings Inc.
13G/A
Amendment 2
ENGN · 29286M105
|
5.9% |
1/29/2025
Event 12/31/2024
|
|||
| Biotechnology Value Fund L P | 3.1% | ||||
| BVF I GP LLC | 3.1% | ||||
| Biotechnology Value Fund II LP | 2.5% | ||||
| BVF II GP LLC | 2.5% | ||||
| Biotechnology Value Trading Fund OS LP | 0.3% | ||||
| BVF Partners OS Ltd. | 0.3% | ||||
| BVF GP Holdings LLC | 5.5% | ||||
| BVF Partners L P/IL | 5.9% | ||||
| BVF Inc/IL | 5.9% | ||||
| Lampert Mark N | 5.9% | ||||
|
XOMA Royalty Corp
13D/A
Amendment 11
XOMA · 98419J206
|
25.3% |
1/28/2025
Event 1/24/2025
|
|||
| Biotechnology Value Fund L P | 12.3% | ||||
| BVF I GP LLC | 12.3% | ||||
| Biotechnology Value Fund II LP | 13.0% | ||||
| BVF II GP LLC | 13.0% | ||||
| Biotechnology Value Trading Fund OS LP | 0% | ||||
| BVF Partners OS Ltd. | 0% | ||||
| BVF GP Holdings LLC | 25.3% | ||||
| BVF Partners L P/IL | 25.3% | ||||
| BVF Inc/IL | 25.3% | ||||
| Lampert Mark N | 25.3% | ||||
|
RAPT Therapeutics, Inc.
13G
RAPT · 75382E109
|
8.7% |
1/6/2025
Event 12/27/2024
|
|||
| Biotechnology Value Fund L P | 4.5% | ||||
| BVF I GP LLC | 4.5% | ||||
| Biotechnology Value Fund II LP | 3.7% | ||||
| BVF II GP LLC | 3.7% | ||||
| Biotechnology Value Trading Fund OS LP | 0% | ||||
| BVF Partners OS Ltd. | 0% | ||||
| BVF GP Holdings LLC | 8.1% | ||||
| BVF Partners L P/IL | 8.7% | ||||
| BVF Inc/IL | 8.7% | ||||
| Lampert Mark N | 8.7% | ||||
|
Inventiva S.A.
13D/A
Amendment 4
IVA · 46124U107
|
9.0% |
12/23/2024
Event 12/19/2024
|
|||
| Biotechnology Value Fund L P | 4.9% | ||||
| BVF I GP LLC | 4.9% | ||||
| Biotechnology Value Fund II LP | 3.5% | ||||
| BVF II GP LLC | 3.5% | ||||
| Biotechnology Value Trading Fund Os, L.P. | 0.4% | ||||
| BVF Partners OS Ltd. | 0.4% | ||||
| BVF GP Holdings LLC | 8.4% | ||||
| BVF Partners L P/IL | 9.0% | ||||
| BVF Inc/IL | 9.0% | ||||
| Lampert Mark N | 9.0% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.